1. Home
  2. CTNM vs GTN Comparison

CTNM vs GTN Comparison

Compare CTNM & GTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • GTN
  • Stock Information
  • Founded
  • CTNM 2009
  • GTN 1897
  • Country
  • CTNM United States
  • GTN United States
  • Employees
  • CTNM N/A
  • GTN N/A
  • Industry
  • CTNM
  • GTN Broadcasting
  • Sector
  • CTNM
  • GTN Industrials
  • Exchange
  • CTNM Nasdaq
  • GTN Nasdaq
  • Market Cap
  • CTNM 453.0M
  • GTN 437.5M
  • IPO Year
  • CTNM 2024
  • GTN N/A
  • Fundamental
  • Price
  • CTNM $17.21
  • GTN $4.70
  • Analyst Decision
  • CTNM Strong Buy
  • GTN Buy
  • Analyst Count
  • CTNM 4
  • GTN 4
  • Target Price
  • CTNM $29.25
  • GTN $6.67
  • AVG Volume (30 Days)
  • CTNM 74.8K
  • GTN 1.5M
  • Earning Date
  • CTNM 11-06-2024
  • GTN 11-08-2024
  • Dividend Yield
  • CTNM N/A
  • GTN 6.82%
  • EPS Growth
  • CTNM N/A
  • GTN 109.53
  • EPS
  • CTNM N/A
  • GTN 1.53
  • Revenue
  • CTNM N/A
  • GTN $3,463,000,000.00
  • Revenue This Year
  • CTNM N/A
  • GTN $17.13
  • Revenue Next Year
  • CTNM N/A
  • GTN N/A
  • P/E Ratio
  • CTNM N/A
  • GTN $3.07
  • Revenue Growth
  • CTNM N/A
  • GTN N/A
  • 52 Week Low
  • CTNM $13.27
  • GTN $3.95
  • 52 Week High
  • CTNM $22.00
  • GTN $10.07
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • GTN 39.84
  • Support Level
  • CTNM N/A
  • GTN $4.19
  • Resistance Level
  • CTNM N/A
  • GTN $6.16
  • Average True Range (ATR)
  • CTNM 0.00
  • GTN 0.30
  • MACD
  • CTNM 0.00
  • GTN -0.13
  • Stochastic Oscillator
  • CTNM 0.00
  • GTN 33.94

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About GTN Gray Television Inc.

Gray Television Inc is a television broadcast company. The company is engaged in owning and operating television stations. It also owns video program production, marketing, and digital business. It has two segments namely, Broadcasting and Production companies. Majority of the revenue is generated from the broadcasting segment which operates television stations in local markets in the United States.

Share on Social Networks: